

Acta Med. Okayama, 2011  
Vol. 65, No. 3, pp. 151–162

Copyright©2011 by Okayama University Medical School.

Acta Medica  
Okayama

<http://escholarship.lib.okayama-u.ac.jp/amo/>

Review

## A Novel Molecular Therapy Using Bioengineered Adenovirus for Human Gastrointestinal Cancer

Toshiyoshi Fujiwara\*

Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

Replication-selective tumor-specific viruses constitute a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Human telomerase is highly active in more than 85% of primary cancers, regardless of their tissue origins, and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector (Telomelysin, OBP-301), in which the hTERT promoter element drives expression of E1 genes. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter would allow for preferential expression of viral genes in tumor cells, leading to selective viral replication and oncolytic cell death. Lymphatic invasion is a major route for cancer cell dissemination, and adequate treatment of locoregional lymph nodes is required for curative treatment in patients with gastrointestinal tumors. We demonstrated that intratumoral injection of Telomelysin mediates effective *in vivo* purging of metastatic tumor cells from regional lymph nodes. Moreover, using noninvasive whole-body imaging, we found that intratumoral injection of Telomelysin followed by regional irradiation induces a substantial antitumor effect, resulting from tumor cell-specific radiosensitization, in an orthotopic human esophageal cancer xenograft model. These results illustrate the potential of oncolytic virotherapy as a promising strategy in the management of human gastrointestinal cancer.

**Key words:** telomerase, adenovirus, metastasis, lymph node, colorectal cancer

Viruses are the simplest form of life carrying genetic materials and are capable of entering host cells efficiently. Because of these properties, many viruses have been adapted as gene transfer vectors [1–3], for which purpose adenoviruses have been well studied and characterized. Adenoviruses are large, double-stranded DNA viruses with tropism for many human tissues such as bronchial epithelia, hepatocytes, and neurons. Furthermore, they are capable

of transducing nonreplicating cells and can be grown to high titers *in vitro*, a feature beneficial for clinical use. High titers of replication-defective adenoviruses can be produced and have been successfully used in eukaryotic gene expression [1, 4, 5]. Numerous studies using *in vitro* and animal models have tested a wide variety of adenoviral gene therapy agents and reported potential beneficial effects for different target diseases, including their tolerability and safety [6–9].

Oncolytic viruses that can selectively replicate in tumor cells and lyse infected cells have been extensively investigated as novel anticancer agents [3, 10,

Received November 25, 2010; accepted February 7, 2011.

\*Corresponding author. Phone: +81-86-235-7257; Fax: +81-86-221-8775

E-mail: [toshi\\_f@md.okayama-u.ac.jp](mailto:toshi_f@md.okayama-u.ac.jp) (T. Fujiwara)

11]. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor cell while remaining innocuous to normal tissues [12]. Onyx-015 is one such adenovirus with the E1B 55-kDa gene deleted, engineered to selectively replicate in and lyse p53-deficient cancer cells; clinical trials of intratumoral injection of Onyx-015 [13] alone or in combination with cisplatin/5-fluorouracil have been conducted in patients with recurrent head and neck cancer [14, 15]. However, a subsequent study clarified that the capacity of Onyx-015 to replicate independently of the cell cycle does not correlate with the status of p53 [16] but is determined by the late viral RNA export [17].

The optimal treatment of human cancer requires improvement of the therapeutic ratio, maximizing the cytotoxic efficacy of an agent on tumor cells while minimizing its effect on normal cells. This may not be an easy task because the majority of normal cells surrounding tumors are sensitive to cytotoxic agents. Thus, to establish reliable therapeutic strategies for human cancer, it is important to seek genetic or epigenetic targets present only in cancer cells. One targeting strategy has involved the use of tissue-specific promoters to restrict gene expression or viral replication in specific tissues. A large number of different tissue-specific promoters have been used for virotherapy applications; however, tumor-specific rather than tissue-specific promoters would be more advantageous targets. For example, the promoter of human telomerase reverse transcriptase (hTERT) is highly active in most tumor cells but inactive in normal somatic cell types.

This review highlights some very promising advances in cancer therapeutic technologies using the hTERT promoter against human gastrointestinal cancer.

### Telomerase Activity for Transcriptional Cancer Targeting

One of the hallmarks of cancer is unregulated proliferation of a certain cell population, which eventually affects normal cellular function in the human body. This process almost universally correlates with the activation of telomerase. Tumor cells can maintain telomere length predominantly due to telomerase, and

its activity is detected in about 85% of malignant tumors [18], whereas telomerase is absent in most normal somatic tissues [19], with a few exceptions including peripheral blood leukocytes and certain stem cell populations [20, 21]. The strong association between telomerase activity and malignant tissue makes telomerase a plausible target for the diagnosis and treatment of cancer [22].

The enzyme telomerase is a ribonucleoprotein complex responsible for the addition of TTAGGG repeats to the telomeric ends of chromosomes, and contains three components: the RNA subunit (known as hTR, hTER, or hTERC) [23], the telomerase-associated protein (hTEP1) [24], and the catalytic subunit (hTERT) [25, 26]. Both hTR and hTERT are required for the reconstitution of telomerase activity *in vitro* [27] and, therefore, represent the minimal catalytic core of telomerase in humans [28]. Both hTR and hTERT transcripts are easily detectable in cancer cells but are either absent or at low levels in normal cells [29]; however, the hTR promoter is always stronger than hTERT with presumably more background [30]. Thus, the hTERT promoter region can be substantially used as a fine-tuning molecular switch that works exclusively in tumor cells (Fig. 1).

### hTERT Promoter-driven Telomerase-specific Oncolytic Adenovirus

The use of modified adenoviruses that replicate and complete their lytic cycle preferentially in cancer cells is a promising strategy for the treatment of cancer. One approach to achieving tumor specificity of viral replication is based on the transcriptional control of genes that are critical for virus replication such as *E1A* or *E4*. As described above, telomerase, especially its catalytic subunit hTERT, is expressed in the majority of human cancers, and the hTERT promoter is preferentially activated in human cancer cells [18]. Thus, the broadly applicable hTERT promoter might be a suitable regulator of adenoviral replication. Indeed, it has been reported previously that the transcriptional control of *E1A* expression via the hTERT promoter could restrict adenoviral replication to telomerase-positive tumor cells and efficiently lyse tumor cells [31–36]. Furthermore, Kuppuswamy *et al.* have recently developed a novel oncolytic adenovirus




Fig. 1 Scheme of the proximal promoter of hTERT. Putative protein-binding sites for various transcription factors are indicated.

(VRX-011), in which the replication of the vector targets cancer cells by replacing an adenovirus E4 promoter with the hTERT promoter [37]. VRX-011 could also overexpress the adenovirus death protein (ADP) (also known as E3-11.6K), which is required for efficient cell lysis and release of virions from cells at late stages of infection.

The adenovirus *E1B* gene is expressed early in viral infection and its gene product inhibits E1A-induced p53-dependent apoptosis, which in turn promotes the cytoplasmic accumulation of late viral mRNA, leading to a shut-down of host cell protein synthesis. In most vectors that replicate under the transcriptional control of the *E1A* gene including hTERT-specific oncolytic adenoviruses, the *E1B* gene is driven by the endogenous adenovirus E1B promoter. However, Li *et al.* [38] have demonstrated that transcriptional control of both *E1A* and *E1B* genes by the  $\alpha$ -fetoprotein (AFP) promoter with the use of IRES significantly improved the specificity and the therapeutic index in hepatocellular carcinoma cells. Based on the above information, we developed Telomelysin (OBP-301), in which the tumor-specific hTERT promoter regulates both the *E1A* and *E1B* genes (Fig. 2). Telomelysin is expected to control viral replication more stringently, thereby providing better therapeutic effects in tumor cells as well as attenuated toxicity


in normal tissues [39].

### ***In Vitro* and *In Vivo* Antitumor Efficacy of Telomelysin in Human Gastrointestinal Cancer**

As the majority of human cancer cells acquire immortality and unregulated proliferation by expression of hTERT [18], hTERT-specific Telomelysin could theoretically possess a broad-spectrum antineoplastic activity against a variety of human tumors [39, 40]. Telomelysin induced selective E1A and E1B expression in cancer cells, which resulted in viral replication at 5-6 logs by 3 days after infection; on the other hand, Telomelysin replication was attenuated up to 2 logs in cultured normal cells [39, 40].

*In vitro* cytotoxicity assays demonstrated that Telomelysin could efficiently kill various types of human gastrointestinal cancer cell lines including esophageal cancer, gastric cancer, and colorectal cancer in a dose-dependent manner [41]. These data clearly demonstrate that Telomelysin exhibits desirable features for use as an oncolytic therapeutic agent, as the proportion of cancers potentially treatable by Telomelysin is extremely high.

The *in vivo* antitumor effect of Telomelysin was also investigated using athymic mice carrying xenografts, because most murine tumor cells are known to express



**Fig. 2** Structures of telomerase-specific oncolytic adenoviruses. Telomelysin (OBP-301), in which the hTERT promoter element drives the expression of *E1A* and *E1B* genes linked with an internal ribosome entry site. TelomeScan (OBP-401) is a telomerase-specific replication-competent adenovirus variant, in which the *GFP* gene is inserted under a cytomegalovirus promoter into the E3 region for monitoring viral replication. *Left panel*, schematic representation depicting major structural components of adenoviruses (hexon, penton base, and fiber).

low levels of the coxsackievirus and adenovirus receptor (CAR). Intratumoral injection of Telomelysin into human colorectal tumor xenografts resulted in a significant inhibition of tumor growth and enhancement of survival [39, 40]. Macroscopically, massive ulceration was noted on the tumor surface after injection of high-dose Telomelysin, indicating that Telomelysin induced intratumoral necrosis due to direct lysis of tumor cells by virus replication *in vivo* [42].

### Lymph Node Metastasis in Human Gastrointestinal Cancer

Lymph node status provides important information for both the diagnosis and treatment of human gastrointestinal cancer. Lymphatic invasion is a major route for cancer cell dissemination, and lymph node metastasis represents aggressive tumor behavior and is associated with high rates of regional recurrence, which portends a poor outcome and may produce marked morbidity [43–45]. Therefore, adequate resection of the locoregional lymph nodes is required for curative treatment in patients with gastrointestinal malignancies such as esophageal, gastric, and col-

orectal cancers [46, 47]. Extended lymphadenectomy, however, may greatly impair quality of life, especially for patients with early-stage epithelial neoplasms in the gastrointestinal tract [48]. Their primary tumors can be removed by new endoluminal therapeutic techniques such as endoscopic submucosal dissection; however, patients with submucosal invasion, lymphovascular infiltration of cancer cells, or undifferentiated histology often become candidates for surgical organ resection with lymphadenectomy, because there is a risk of regional lymph node metastasis, although the frequency is relatively low [49]. For example, resection of upper gastrointestinal organs such as gastrectomy and esophagectomy may result in body weight loss and microgastric. A less invasive way to selectively treat lymph node metastasis would benefit these patients by allowing them to avoid prophylactic surgery.

### *In Vivo* Lymphatic Spread of Virus on Regional Lymph Nodes

The therapeutic potential of viral agents against primary tumors as well as their systemic biodistribu-

tion targeting distant metastases has been intensively investigated [3, 10, 50]. Few studies, however, have examined the ability of the virus to progress to the regional draining lymph nodes. Recently, Burton *et al.* showed that replication-deficient adenovirus could be successfully transported to the regional lymph nodes and non-invasively detect metastasis by expressing the prostate-specific reporter gene in an orthotopic prostate xenograft [51].

To verify that oncolytic adenoviruses progress through the lymphatic vessels to the regional lymph nodes, we used an orthotopic mouse model of human rectal cancer with spontaneous lymph node metastasis. We have demonstrated that intratumoral injection of the telomerase-specific replication-selective GFP-expressing adenovirus TelomeScan (OBP-401) (Fig. 2) could efficiently visualize metastatic lymph nodes with GFP fluorescence signals in human cancer xenograft models [52, 53]. These studies suggest the possible application of the adenovirus vectors as a lymphotropic agent for the treatment of lymph node metastasis.

### ***In Vitro* Purging of Human Colorectal Cancer Cells by Telomelysin**

*In vitro* purging experiments demonstrated that Telomelysin infection could selectively eliminate human tumor cells in the presence of human or mouse lymphocytes [54]. We used TelomeScan to visualize viable human tumor cells after purging with Telomelysin, as we have previously shown the high sensitivity and specificity of this molecular imaging method [52, 53]. It has been reported that the fiber-modified adenovirus serotype 5 (Ad5) and an adenovirus vector based on another serotype such as 35 efficiently transduce exogenous genes into hematopoietic cells, including stem cells; the unmodified Ad5, however, could rarely infect these cells because of the lack of CAR expression [55]. Indeed, Ad5-based Telomelysin had no apparent effects on the viability of lymphocytes *in vitro*. These results suggest that normal lymphocytes in the regional lymph nodes could be strictly protected from Telomelysin-induced oncolysis because lymphocytes are not subject to Telomelysin infection and viral replication is also unlikely to occur in normal cells due to their low telomerase activity [20].

### ***In Vivo* Antitumor Effect of Telomelysin on Lymph Node Metastasis**

Mice bearing orthotopic human colorectal tumors received 3 rounds of intratumoral injection of Telomelysin at 2-day intervals beginning 2 weeks after the tumor inoculation. Histopathological examination of the excised total lymph nodes showed that Telomelysin treatment considerably reduced the metastatic rates. We also used a simple real-time *Alu* PCR assay to quantify the few metastatic human tumor cells against a background of large numbers of mouse host cells [54]. This human-specific amplification method enabled us to detect human tumor cells in a linear range of  $10^3$ – $10^8$  cells/sample and to monitor the time-dependent exponential growth of spontaneous lymph node metastasis from orthotopic colorectal tumor xenografts. In accordance with the histologically confirmed results, the *Alu* PCR assay indicated that intratumoral injection of Telomelysin into the primary tumors significantly inhibited lymph node metastasis with high levels of viral replication.

We also used TelomeScan and a three-dimensional optical detection system (IVIS 200) (Xenogene, Alameda, CA, USA) to compare the extent of metastasis after Telomelysin and control treatments. After 2 weeks of orthotopic implantation of human colorectal tumor cells, Telomelysin was administered intratumorally for 5 cycles. We then used the IVIS imaging system to explore the abdominal cavity at laparotomy following a single injection of TelomeScan into tumors. The number of GFP-positive lymph nodes and the GFP signal levels of individual lymph nodes were much higher in mock-treated control mice than in Telomelysin-treated mice. Indeed, the sum of GFP fluorescence intensity in the abdominal cavity was significantly lower in mice treated with Telomelysin, confirming the *in vivo* biological purging effect of Telomelysin. The fact that two independent and highly sensitive approaches showed comparable results suggests the potent *in vivo* purging effect of oncolytic virotherapy on regional lymph nodes.

For effective treatment of metastatic tumors, intravenously infused chemotherapeutic drugs must be distributed in sufficient concentrations into the tumor sites; by contrast, oncolytic viruses can replicate in the tumor, cause oncolysis, and then release virus particles that could reach distant metastatic lesions.

Moreover, intratumoral injection can avoid the hepatotoxicity that may be induced by systemic adenoviral administration. Therefore, low-dose intratumoral administration of oncolytic virus that causes the replication and release of newly formed viruses from tumor cells may be safer than traditional full-dose chemotherapy, and certainly, intratumoral administration of the virus allows for a safer dose than would its systemic administration.

### **Preoperative Intratumoral Administration of Telomelysin against Lymph Node Metastasis**

Currently, surgery and radiation are the most effective and clinically reliable local management strategies for human malignancies including lymphatic metastases. Ionizing radiation targeting the lower half of the mouse body including primary tumors and the para-aortic lymphatic area did significantly inhibit lymph node metastasis, but systemic toxicity indicated by symptoms such as body weight loss was remarkable in irradiated mice compared to mice treated with Telomelysin. In fact, total body irradiation at a dose of 10Gy has been reported to be lethal in mice because of acute radiation syndromes involving the hematopoietic system and gastrointestinal tract [56]. We demonstrated that regional injection of Telomelysin might be simpler and safer than radiotherapy as a treatment for metastatic lymph nodes [54].

We also assessed the effect of surgical resection of primary rectal tumors on lymph node metastasis. Unexpectedly, metastatic tumor cells in the lymph nodes considerably increased after surgical removal of primary rectal tumors, presumably due to the spread of tumor cells into the lymphatic circulation during the surgical procedure. Another possible explanation of this phenomenon includes a decrease in angiogenic inhibitors such as angiostatin and endostatin secreted from the primary tumor mass [57]. In contrast, intratumoral injection of Telomelysin prior to surgical resection significantly inhibited lymph node metastasis. Telomelysin causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in eradication of lymph node metastasis. Tumor cells infected with Telomelysin in the primary tumors are also unable to metastasize to the regional lymph nodes. Therefore, although the surgi-


cal procedure itself has the potential to promote regional metastasis, preoperative treatment with Telomelysin may prevent this undesirable event.

### **Ionizing Radiation and DNA Repair Machinery**


Current treatment strategies for advanced cancer include surgical resection, radiation, and cytotoxic chemotherapy. Preoperative or postoperative chemoradiation may improve local control and the survival of advanced cancer patients by minimizing the risk of dissemination during the surgical procedure, increasing the complete resection rate, and eradicating microscopic residual tumor cells that are not surgically removed. The lack of restricted selectivity for tumor cells is the primary limitation of radiotherapy, despite improved technologies such as stereotactic and hyperfractionated radiotherapy. Although radiotherapy is generally considered to be less invasive, the maximum doses and treatment fields are limited to avoid cytotoxic effects on the surrounding normal tissues. Therefore, to improve the therapeutic index of radiotherapy, there is a need for agents that effectively lower the threshold for radiation-induced tumor cell death while not compromising the tolerance of normal cells. The safety and efficacy of some candidates are already being explored in clinical trials [58–60].

Ionizing radiation primarily targets DNA molecules and induces double-strand breaks (DSBs) [61]. Radiosensitization can result from a therapeutic increase in DNA DSBs or inhibition of their repair. Ataxia-telangiectasia-mutated (ATM) protein is an important signal transducer of the DNA damage response, which contains DNA repair and cell-cycle checkpoints, and activation of ATM by autophosphorylation occurs in response to exposed DNA DSBs [62]. Cells with ATM gene mutations have defects in cell-cycle checkpoints and DNA repair and are hypersensitive to DSBs [63, 64]; thus, agents that inhibit the ATM pathway can be useful radiosensitizers [65]. The MRN complex, consisting of Mre11, Rad50 and NBS1, is quickly stimulated by DSBs and directly activates ATM [66, 67] (Fig. 3). Defects in the MRN complex lead to genomic instability, telomere shortening and hypersensitivity to DNA damage [68].

## DNA Repair Mechanism after Radiation



## Telomelysin Blocks the Repair of DNA Damages



**Fig. 3** Molecular mechanism of Telomelysin-induced radiosensitization. The MRN complex plays a role as an upstream sensor in response to DSBs. Degradation of the MRN complex by the E1B55K protein prevents ATM autophosphorylation and signaling, leading to the inhibition of the ATM-dependent G<sub>2</sub>/M checkpoint.

### Telomelysin Sensitizes Human Cancer Cells to Ionizing Radiation

Virus infection and replication produce exogenous viral proteins, many of which manipulate the host cellular machinery to allow viral persistence in the life-cycle. The adenovirus *E1B* gene encodes a 19-kDa polypeptide (E1B19kDa) and a 55-kDa protein (E1B55kDa). These gene products are expressed early in viral infection and promote the cytoplasmic accumulation of late viral mRNA, leading to a shutoff of host cell protein synthesis. The E1B55kDa protein induces a cellular environment conducive to viral protein synthesis via a complex with the E4orf6 protein [69]. This E1B55kDa/E4orf6 complex degrades the MRN complex, blocks downstream ATM signaling, and leads to a defective G<sub>2</sub>/M checkpoint in response to DSBs [67]. Although the impact of E1B55kDa-mediated disruption of the MRN-ATM pathway on the DNA damage responses triggered by ionizing radiation

has not yet been studied, we demonstrated that Telomelysin-mediated E1B55kDa expression induced the degradation of all components of the MRN complex, which in turn prevented ATM autophosphorylation following ionizing radiation [70] (Fig. 3). Telomelysin expresses the *E1B* gene under the control of the hTERT promoter through an internal ribosome entry site sequence, whereas dl1520 (Onyx-015, CI-1042), which has been used in many clinical trials, was genetically modified by disruption of the coding sequence of the E1B55kDa protein [13]. Therefore, ionizing radiation-induced ATM activation was blocked more efficiently by Telomelysin than by dl1520, which lacks E1B55kDa, although dl1520 slightly inhibited ATM phosphorylation, presumably due to E4orf6 protein expression [71].

Our *in vitro* studies suggest that Telomelysin infection and ionizing radiation may mutually sensitize human tumor cells, potentially leading to an effective combination treatment. Telomelysin infection requires

a period of replication to induce the cytopathic effect and to sensitize cells to radiation, whereas ionizing radiation immediately causes DNA DSBs. Therefore, in a true clinical setting, multiple cycles of the external-beam radiotherapy followed by intratumoral injection of Telomelysin may yield optimal results. We confirmed the synergistic antitumor effect of three cycles of treatment with Telomelysin plus regional radiation and the *in vivo* induction of apoptotic cell death on subcutaneous human tumor xenografts. The orthotopic implantation of tumor cells, however, restores the correct tumor-host interactions, which do not occur when tumors are implanted in ectopic subcutaneous sites [72]. Thus, we also demonstrated the significant synergy of combined treatments in an orthotopic mouse model of human esophageal cancer by using a noninvasive whole-body imaging system.

### Clinical Application of Telomelysin

Preclinical models suggested that Telomelysin could selectively kill a variety of human cancer cells *in vitro* and *in vivo* via intracellular viral replication regulated by hTERT transcriptional activity. Pharmacological and toxicological studies in mice and cotton rats demonstrated that none of the animals treated with Telomelysin showed signs of viral distress (*e.g.*, ruffled fur, weight loss, lethargy, or agitation) or histopathological changes in any organs at autopsy. These promising data led us to design a phase I clinical trial of Telomelysin as a monotherapy.

The protocol "A phase I study of intratumoral injection with telomerase-specific replication-competent oncolytic adenovirus, Telomelysin (OBP-301) for various solid tumors," sponsored by Oncolys BioPharma, Inc. (Minato-ku, Tokyo, Japan), is an open-label, phase I, 3-cohort dose-escalation study [73, 74]. The trial commenced following approval of the US Food and Drug Administration (FDA) in October, 2006. The study to assess the safety, tolerability, and feasibility of intratumoral injection of the agent in patients with advanced solid cancer has been completed. The doses of Telomelysin were escalated from low to high virus particles (VP) in one-log increments. Sixteen patients with a variety of solid tumors such as melanoma, head and neck cancer, breast cancer, lung cancer, and sarcomas were treated with a single-dose intratumoral injection of

Telomelysin and then monitored over one month.

All patients received Telomelysin without dose-limiting toxicity. Common grade 1 and 2 toxicities included injection site reactions (pain, induration) and systemic reactions (fever, chills). The data obtained on the pharmacokinetics and biodistribution of Telomelysin may be of interest. Clinical trials of intratumoral and intravenous administration of CG7870, a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue, demonstrated a second peak of the virus genome in the plasma [75, 76], suggesting active viral replication and shedding into the bloodstream. In fact, circulating viral DNA was transiently (< 6 h after injection) detected in plasma in 13 of 16 patients within 24 h after injection. This dose-dependent initial peak in circulating virus was followed by a rapid decline; however, three patients demonstrated evidence of prolonged viral replication through detection of plasma viral DNA at days 7 and 14, suggesting Telomelysin replication in primary tumors. One of these 3 had disappearance of the injected malignant lesion and loco-regional uninjected satellite nodules, fulfilling a definition of complete response at day 28. Seven patients fulfilled the RECIST definition for stable disease by day 56 after treatment, while 6 patients showed 6.6 to 43% tumor size reduction. Thus, Telomelysin appears well-tolerated and warrants further clinical studies for solid cancer.

### Perspectives

There have been very impressive advances in our understanding of the molecular aspects of human gastrointestinal cancer and in the development of technologies for genetic modification of viral genomes. Transcriptional targeting is a powerful tool for tumor selectivity in cancer therapy, and the hTERT-specific oncolytic adenovirus achieves a more strict targeting potential due to the amplified effect by viral replication. Several independent studies using different regions of the hTERT promoter and different sites of the adenoviral genome responsible for viral replication have shown that the hTERT promoter allows adenoviral replication as a molecular switch and induces selective cytopathic effects in a variety of human tumor cells [31–33, 39–41]. Among these viral constructs, to the best of our knowledge, Telomelysin



seems to be the first hTERT-dependent oncolytic adenovirus that has been used in a clinical trial based on preclinical pharmacological and toxicological studies. Thus, this telomerase-specific targeted oncolytic adenovirus holds promise for the treatment of human cancer.

It has been shown that Telomelysin delivered to the primary tumor site could spread into the regional draining lymphatic vessels, selectively replicate in neoplastic foci, and then reduce the number of tumor cells in metastatic lymph nodes in an orthotopic human colorectal cancer xenograft model [54]. This virus-mediated molecular surgery for lymph node metastasis mimics the clinical scenario of lymphadenectomy; the technique, however, seems to be safer and less invasive. Moreover, we demonstrated that preoperative delivery of Telomelysin into primary tumors prevented the exacerbation of lymph node metastasis by surgical procedures. Telomelysin may offer advantages over other oncolytic viruses targeting lymphatic metastasis, as its safety profile as well as biodistribution pattern after intratumoral delivery have already been confirmed in a phase I clinical trial for various types of solid tumors [73, 74]. Our study provides evidence for the *in vivo* purging effect of Telomelysin in regional lymph nodes that is sufficiently reliable to support this approach.

A possible future direction for Telomelysin includes combination therapy with conventional therapies such as chemotherapy, radiotherapy, surgery, immunotherapy, and new modalities such as antiangiogenic therapy. Since the results of a phase I clinical trial demonstrated that even partial elimination of the tumor induced by intratumoral injection of Telomelysin could be clinically beneficial, combination approaches may lead to the development of more advanced biological therapy for human cancer. The combination of systemic chemotherapy and local injection of Telomelysin has been previously shown to be effective [77–79]. As a replication-deficient adenovirus could replicate in cancer cells and enhance the anticancer effect when co-transfected with Telomelysin, which can produce the E1 protein, we demonstrated the synergistic effects of Telomelysin combined with an E1-deleted replication-deficient adenoviral vector expressing the human wild-type p53 tumor suppressor gene (Ad5CMV-p53, Advexin) [80, 81]. As described above, Telomelysin is also synergistic with ionizing

radiation against human esophageal cancer cells, and we clarified the E1B55kDa-mediated mechanism used by Telomelysin to inhibit DNA repair. Peri- or post-operative administration of Telomelysin may also be valuable as an adjuvant therapy in areas of microscopic residual disease at tumor margins to prevent recurrence or regrowth of tumors.

The field of targeted oncolytic virotherapy is progressing considerably and is rapidly gaining medical and scientific acceptance. Although many technical and conceptual problems await solutions, ongoing and future clinical studies will no doubt continue to provide important clues that may allow substantial progress in human gastrointestinal cancer therapy. Thus, phase II studies of telomerase-specific virotherapy in human cancer patients are warranted.

## References

1. Kaplan JM: Adenovirus-based cancer gene therapy. *Curr Gene Ther* (2005) 5: 595–605.
2. Guo ZS, Thorne SH and Bartlett DL: Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. *Biochim Biophys Acta* (2008) 1785: 217–231.
3. Kirn DH and Thorne SH: Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. *Nat Rev Cancer* (2009) 9: 64–71.
4. Mizuguchi H and Kay MA: Efficient construction of a recombinant adenovirus vector by an improved *in vitro* ligation method. *Hum Gene Ther* (1998) 9: 2577–2583.
5. Stone D and Lieber A: New serotypes of adenoviral vectors. *Curr Opin Mol Ther* (2006) 8: 423–431.
6. Wilson JM, Engelhardt JF, Grossman M, Simon RH and Yang Y: Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial. *Hum Gene Ther* (1994) 5: 501–519.
7. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT and Danel C: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. *Nat Genet* (1994) 8: 42–51.
8. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T, Mastrangeli A, Sanders A, Cooke J and Harvey BG: Phase I study of direct administration of a replication deficient adenovirus vector containing the *E. coli* cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. *Hum Gene Ther* (1997) 8: 985–1001.
9. Serman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM and Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. *Hum Gene Ther* (1998) 9: 1083–1092.
10. Liu TC, Galanis E and Kirn D: Clinical trial results with oncolytic

- virotherapy: a century of promise, a decade of progress. *Nat Clin Pract Oncol* (2007) 4: 101–117.
11. Fujiwara T: Telomerase-specific virotherapy for human squamous cell carcinoma. *Expert Opin Biol Ther* (2009) 9: 321–329.
  12. Hawkins LK, Lemoine NR and Kirn D: Oncolytic biotherapy: a novel therapeutic platform. *Lancet Oncol* (2002) 3: 17–26.
  13. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. *Science* (1996) 274: 373–376.
  14. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK and Kirn DH: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* (2000) 6: 879–885.
  15. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S and Kirn D: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. *J Clin Oncol* (2001) 19: 289–298.
  16. Goodrum FD and Ormelles DA: p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. *J Virol* (1998) 72: 9479–9490.
  17. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D and McCormick F: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. *Cancer Cell* (2004) 6: 611–623.
  18. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. *Eur J Cancer* (1997) 33: 787–791.
  19. Dong CK, Masutomi K and Hahn WC: Telomerase: regulation, function and transformation. *Crit Rev Oncol Hematol* (2005) 54: 85–93.
  20. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S and Yamakido M: Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. *J Immunol* (1995) 155: 3711–3715.
  21. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, Ishikawa F, Tahara E and Ide T: Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. *Oncogene* (1999) 18: 1561–1567.
  22. Shay JW and Wright WE: Telomerase: a target for cancer therapeutics. *Cancer Cell* (2002) 2: 257–265.
  23. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC and Yu J: The RNA component of human telomerase. *Science* (1995) 269: 1236–1241.
  24. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I and Robinson MO: A mammalian telomerase-associated protein. *Science* (1997) 275: 973–977.
  25. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA and Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. *Cell* (1997) 90: 785–795.
  26. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. *Science* (1997) 277: 955–959.
  27. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T and Ishikawa F: Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. *Nat Genet* (1998) 18: 65–68.
  28. Beattie TL, Zhou W, Robinson MO and Harrington L: Reconstitution of human telomerase activity in vitro. *Curr Biol* (1998) 8: 177–180.
  29. Keith WN, Sarvesvaran J and Downey M: Analysis of telomerase RNA gene expression by in situ hybridization. *Methods Mol Biol* (2002) 191: 65–81.
  30. Bilsland AE, Merron A, Vassaux G and Keith WN: Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. *Cancer Res* (2007) 67: 1299–1307.
  31. Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S and Kuhnel F: A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. *Cancer Res* (2003) 63: 3181–3188.
  32. Larson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK and Wang G: Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. *Cancer Res* (2003) 63: 7936–7941.
  33. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS and Majumdar AS: Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. *Cancer Gene Ther* (2004) 11: 174–185.
  34. Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J, Sohn JH, Kim H and Yun CO: Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. *Hum Gene Ther* (2003) 14: 1415–1428.
  35. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV and Woo SL: Telomerase-dependent oncolytic adenovirus for cancer treatment. *Gene Ther* (2003) 10: 1241–1247.
  36. Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z, Qian C and Liu X: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. *Oncogene* (2004) 23: 457–464.
  37. Kuppaswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS and Toth K: Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. *Gene Ther* (2005) 12: 1608–1617.
  38. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N and Henderson DR: A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. *Cancer Res* (2001) 61: 6428–6436.
  39. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, Taki M, Kyo S, Tanaka N and Fujiwara T: Telomerase-specific replication-selective virotherapy for human cancer. *Clin Cancer Res* (2004) 10: 285–292.
  40. Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N and Fujiwara T: Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). *Oncogene* (2005) 24: 3130–3140.
  41. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H, Nagai K, Tanaka N, Kumon H, Urata Y and Fujiwara T: Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. *Cancer Sci* (2008) 99: 385–390.
  42. Fujiwara T, Urata Y and Tanaka N: Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. *Curr*

- Cancer Drug Targets (2007) 7: 191–201.
43. Maehara Y, Oshiro T, Endo K, Baba H, Oda S, Ichiyoshi Y, Kohnoe S and Sugimachi K: Clinical significance of occult micro-metastasis lymph nodes from patients with early gastric cancer who died of recurrence. *Surgery* (1996) 119: 397–402.
  44. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM and Osborne MP: Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. *J Am Coll Surg* (2000) 191: 1–6.
  45. Chang GJ, Rodriguez-Bigas MA, Skibber JM and Moyer VA: Lymph node evaluation and survival after curative resection of colon cancer: systematic review. *J Natl Cancer Inst* (2007) 99: 433–441.
  46. Volpe CM, Koo J, Miloro SM, Driscoll DL, Nava HR and Douglass HO, Jr.: The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. *J Am Coll Surg* (1995) 181: 56–64.
  47. Harrison LE, Karpeh MS and Brennan MF: Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. *J Gastrointest Surg* (1998) 2: 126–131.
  48. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y and Okajima K: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* (2008) 359: 453–462.
  49. Gotoda T, Sasako M, Ono H, Katai H, Sano T and Shimoda T: Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. *Br J Surg* (2001) 88: 444–449.
  50. Liu TC and Kirn D: Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. *Cancer Res* (2007) 67: 429–432.
  51. Burton JB, Johnson M, Sato M, Koh SB, Mulholland DJ, Stout D, Chatziioannou AF, Phelps ME, Wu H and Wu L: Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. *Nat Med* (2008) 14: 882–888.
  52. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F, Teraishi F, Kyo S, Mizuguchi H, Hashimoto Y, Urata Y, Tanaka N and Fujiwara T: In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. *Nat Med* (2006) 12: 1213–1219.
  53. Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S and Fujiwara T: Telomerase-specific virotheranostics for human head and neck cancer. *Clin Cancer Res* (2009) 15: 2335–2343.
  54. Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, Ouchi M, Tazawa H, Uno F, Kagawa S, Kyo S, Mizuguchi H, Urata Y, Tanaka N and Fujiwara T: In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. *Ann Surg* (2010) 251: 1079–1086.
  55. Kawabata K, Sakurai F, Koizumi N, Hayakawa T and Mizuguchi H: Adenovirus vector-mediated gene transfer into stem cells. *Mol Pharm* (2006) 3: 95–103.
  56. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E and Gudkov AV: An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. *Science* (2008) 320: 226–230.
  57. Folkman J: Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* (2002) 29: 15–18.
  58. Bentzen SM, Harari PM and Bernier J: Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. *Nat Clin Pract Oncol* (2007) 4: 172–180.
  59. Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G and Mehta MP: Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. *Neuro Oncol* (2008) 10: 752–758.
  60. Hoskin P, Rojas A and Saunders M: Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study. *Int J Radiat Oncol Biol Phys* (2009) 73: 1425–1431.
  61. Kim CH, Park SJ and Lee SH: A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. *J Pharmacol Exp Ther* (2002) 303: 753–759.
  62. Tang X, Hui ZG, Cui XL, Garg R, Kastan MB and Xu B: A novel ATM-dependent pathway regulates protein phosphatase 1 in response to DNA damage. *Mol Cell Biol* (2008) 28: 2559–2566.
  63. Shiloh Y: Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. *Annu Rev Genet* (1997) 31: 635–662.
  64. Petrini JH: The Mre11 complex and ATM: collaborating to navigate S phase. *Curr Opin Cell Biol* (2000) 12: 293–296.
  65. Sturgeon CM and Roberge M: G2 checkpoint kinase inhibitors exert their radiosensitizing effects prior to the G2/M transition. *Cell Cycle* (2007) 6: 572–575.
  66. D'Amours D and Jackson SP: The Mre11 complex: at the crossroads of dna repair and checkpoint signalling. *Nat Rev Mol Cell Biol* (2002) 3: 317–327.
  67. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV and Weitzman MD: The Mre11 complex is required for ATM activation and the G2/M checkpoint. *EMBO J* (2003) 22: 6610–6620.
  68. Theunissen JW, Kaplan MI, Hunt PA, Williams BR, Ferguson DO, Alt FW and Petrini JH: Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11 (ATLD1/ATLD1) mice. *Mol Cell* (2003) 12: 1511–1523.
  69. Blackford AN and Grand RJ: Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. *J Virol* (2009) 83: 4000–4012.
  70. Kuroda S, Fujiwara T, Shirakawa Y, Yamasaki Y, Yano S, Uno F, Tazawa H, Hashimoto Y, Watanabe Y, Noma K, Urata Y, Kagawa S and Fujiwara T: Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. *Cancer Res* (2010) 70: 9339–9348.
  71. Hart LS, Yannone SM, Naczki C, Orlando JS, Waters SB, Akman SA, Chen DJ, Ornelles D and Koumenis C: The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. *J Biol Chem* (2005) 280: 1474–1481.
  72. Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. *Cancer Metastasis Rev* (1986) 5: 29–49.
  73. Fujiwara T, Tanaka N, Numunaitis JJ, Senzer NN, Tong A, Ichimaru D, Shelby SM, Hashimoto Y, Kawamura H and Urata Y: Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: Evaluation of biodistribution and immune response. *J Clin Oncol* (2008) 26: 3572.
  74. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B,

- Burke J, Ichimaru D, Urata Y and Fujiwara T: A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. *Mol Ther* (2010) 18: 429–434.
75. DeWeese TL, van der PH, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG and Simons JW: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res* (2001) 61: 7464–7472.
76. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van UL, Yu DC, Aimi J, Ando D, Working P, Kim D and Wilding G: A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. *Mol Ther* (2006).
77. Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N and Fujiwara T: Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy. *Int J Cancer* (2006) 119: 432–440.
78. Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N and Fujiwara T: Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. *Exp Cell Res* (2006) 312: 256–265.
79. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y and Fujiwara T: Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. *Mol Cancer Ther* (2009) 8: 980–987.
80. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T, Yoshimura K, Sato T, Eto Y, Chada S, Nakamura H and Kato H: Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. *J Clin Oncol* (2006) 24: 1689–1699.
81. Sakai R, Kagawa S, Yamasaki Y, Kojima T, Uno F, Hashimoto Y, Watanabe Y, Urata Y, Tanaka N and Fujiwara T: Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. *Mol Cancer Ther* (2010) 9: 1884–1893.